S. G. Turville

This study tracks SARS-CoV-2 evolution through 33-100 serial passages in vitro, identifying convergent mutations that may confer fitness or transmissibility advantages.

The paper shows Omicron SARS-CoV-2 lineages rely on ACE2 without TMPRSS2 complexes for entry, due to changes in the ACE2 Collectrin-Like Domain affecting TMPRSS2 activation.

This paper discovers a macrocyclic peptide that inhibits SARS-CoV-2 and related sarbecoviruses by targeting a conserved site in the spike protein, offering a potential broad-spectrum antiviral.

This paper modifies the SARS-CoV-2 spike protein to enhance thermal stability and neutralizing antibody response against ancestral and Delta variants, but reduced effectiveness against Omicron BA.1.

This paper isolates broadly neutralizing SARS-CoV-2 antibodies from convalescent patients and shows they neutralize emerging variants more effectively than existing monoclonal antibodies.

This study shows Lenacapavir's antiviral effect comes from hyperstabilizing the HIV-1 capsid lattice, leading to loss of compartmentalization and capsid failure.

This study identifies cyclic peptides targeting SARS-CoV-2 main protease using mRNA display, showing antiviral activity in vitro.

The paper identifies cyclic peptide ligands to the SARS-CoV-2 spike protein RBD using mRNA display, finding six high-affinity molecules with nanomolar dissociation constants.

This paper develops a fluorescence fluctuation spectroscopy method to rapidly screen HIV-1 capsid interactors by detecting binding events in solution.

The paper identifies HIV's manipulation of the Arp2/3-Cdc42-IQGAP1 pathway to hijack cortical F-Actin for cell-cell viral spread, showing that this process prevents particle release but enables infection through maturation of contacts.